Aigen Investment Management LP Invests $257,000 in Genmab A/S (NASDAQ:GMAB)

Aigen Investment Management LP acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 12,292 shares of the company's stock, valued at approximately $257,000.

A number of other hedge funds have also modified their holdings of GMAB. Two Sigma Advisers LP raised its stake in shares of Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares during the last quarter. FMR LLC increased its stake in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after buying an additional 33,076 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in shares of Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock valued at $5,662,000 after buying an additional 14,165 shares during the last quarter. Natixis Advisors LLC grew its holdings in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock worth $5,036,000 after acquiring an additional 47,437 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new stake in Genmab A/S in the 4th quarter valued at about $3,692,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and an average target price of $41.33.

Remove Ads

Genmab A/S Stock Down 1.2 %

NASDAQ GMAB traded down $0.25 during trading on Thursday, reaching $19.96. 1,374,871 shares of the stock traded hands, compared to its average volume of 899,063. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The firm has a market cap of $13.21 billion, a price-to-earnings ratio of 11.47, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The stock's 50-day moving average price is $21.28 and its 200 day moving average price is $22.52.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.